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Abstract
Background & Purpose: Rectal toxicity is less common after 125I seed implant brachytherapy for prostate cancer,
and intraoperative rectal dose-volume constraints (the constraint) is still undetermined in pioneering studies. As our
constraint failed to prevent grade 2 or 3 rectal bleeding (bled-pts) in 5.1% of patients, we retrospectively explored
another constraint for the prevention of rectal bleeding.
Materials and methods: The study population consisted of 197 patients treated with the brachytherapy as
monotherapy using real-time intraoperative transrectal ultrasound (US)-guided treatment at a prescribed dose of 145
Gy. Post-implant dosimetry was performed on Day 1 and Day 30 after implantation using computed tomography (CT)
imaging. Rectal bleeding toxicity was classified by CTC-AE ver. 3.0 during a mean 29-month (range, 12-48 months)
period after implantation. The differences in rV100s were compared among intraoperative, Day 1 and Day 30 dosimetry,
and between that of patients with grade 2 or 3 rectal bleeding (the bled-pts) and of the others (the spared-pts). All
patients were divided into groups based on provisional rV100s that were increased stepwise in 0.1-cc increments from
0 to 1.0 cc. The difference in the ratios of the bled-pts to the spared-pts was tested by chi-square tests, and their odds
ratios were calculated (bled-OR). All statistical analyses were performed by t-tests.
Results: The mean values of rV100us, rV100CT_1, and rV100CT_30 were 0.31 ± 0.43, 0.22 ± 0.36, and 0.59 ± 0.68 cc,
respectively. These values temporarily decreased (p = 0.020) on Day 1 and increased (p = 0.000) on Day 30. There
was no significant difference in rV100s between the bled-pts and spared-pts at any time of dosimetry. The
maximum bled-OR was identified among patients with an rV100us value above 0.1 cc (p = 0.025; OR = 7.8; 95% CI,
1.4-145.8); an rV100CT_1 value above 0.3 cc (p = 0.014; OR = 16.2; 95% CI, 3.9-110.7), and an rV100CT_30 value
above 0.5 cc (p = 0.019; OR = 6.3; 95% CI, 1.5-42.3).
Conclusion: By retrospective analysis exploring rV100 as intraoperative rectal dose-volume thresholds in 125I seed
implant brachytherapy for prostate cancer, it is proved that rV100 should be less than 0.1 cc for preventing rectal
bleeding.
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Introduction
When compared to external beam radiotherapy rectal
toxicity is less common after 125I seed implant bra-
chytherapy for prostate cancer [1], the proximity of the
posterior margin of the prostate to the rectal anterior
wall compromises the latter’s sparing and induces post-
implant proctitis, rectal ulcerations, or fistulas, even
after prostate seed implant brachytherapy [2,3]. The
close correlation between these adverse effects and rec-
tal irradiation exposure volume has been demonstrated
by dose-volume histogram (DVH) analysis using com-
puted tomography (CT) images obtained several weeks
after brachytherapy. Snyder et al. found a significantly
higher frequency of grade-2 proctitis in patients with
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rectal irradiation exposure volume at a prescribed dose
(rV100) greater than 1.3 cc [4]. Waterman et al. also
reported that the probability of late rectal morbidity
depends both on the dose and on the rectal surface area
exposed to 100 Gy radiations [5]. These dose-volume
thresholds of the rectal wall could not be adopted as
intraoperative constraints for brachytherapy because of
discrepancies in dose distribution between intraoperative
ultrasound (US)-based and postoperative CT-based dosi-
metry [6-8]. To date, there appears to be no definitive
agreement regarding rV100 constraints during interac-
tive dose assessments. Some investigators have adopted
presumptive rV100 constraints, such as 1.0 cc [9], while
others have neglected to apply any safe range with
rV100 [6].
We initiated seed implantation brachytherapy with a
presumptive rV100 constraint of less than 1.0 cc. How-
ever, it has since become clear that most patients who
develop rectal bleeding have been exposed to an rV100
of less than 1.0 cc. This retrospective study was aimed
at exploring the rV100 value thresholds that had been
established prospectively, could have prevented the
development of rectal bleeding, an infrequent but
intractable morbidity resulting from seed implant
monotherapy.
Materials and methods
The study population comprised 197 patients with
organ-confined prostate cancer who were treated with
125I seed implantation brachytherapy from December
2004 to November 2008 at our hospital, according to a
protocol approved by the institutional review board.
Every patient provided written consent to participate in
the study. Patients who had previously undergone adju-
vant external beam radiotherapy were excluded from
the study. Patients with high-risk prostate cancer were
included in the study when antecedent hormone therapy
had successfully controlled the disease for over a year.
Patient characteristics are summarized in Table 1. Co-
morbidities of the patients included diabetes mellitus (n
= 26), hemorrhoids (n = 23), and cardiac disorder neces-
sitated anti-coagulants administration (n = 30). Approxi-
mately half of the patients had received hormonal
therapy prior to radiotherapy for a median 7.5 months
(range, 1-48 months), either as the definitive treatment
or as a preparative therapy to achieve volume reduction
in unsuitably large prostates.
Implantation was performed under spinal anesthesia
with the patients reclining in the extended dorsolithot-
omy position, and a biplanar US probe was positioned
in the rectum. Transverse images sliced at a 5 mm dis-
tance from the base to the apex of the prostate were
captured into the planning system (Interplant version
3.2 CMS Japan; Tokyo, Japan, or Variseed version 7.2;
Varian Medical Systems, Palo Alto, CA, USA) for plani-
metric analysis. The prostate, urethra, and the anterior
part of the rectum appeared contoured on each image.
Seeds (SourceTech, Bard, USA; 0.338-0.347 mCi) were
implanted by transrectal US-guided insertion based on a
previously described procedure [10]. The prostate plani-
metry volume was used to determine the radioactive
strength and the number of seeds required. Needles
were placed peripherally on the largest prostate slice on
the transverse image and loaded with seeds using a
Mick applicator (Mick Radionuclear Instruments, New
York, USA), under the guidance of sagittal US imaging.
Seventy five percent of the seeds were placed at regular
intervals along the entire length of the needle within the
prostate; the remaining seeds were inserted into the
inner needles added to cover the underdosed area, typi-
cally located at the base and apex of the prostate gland.
Before addition of the inner needles, the US images
were re-captured to catch up with prostate swelling and
urethral stretching by peripheral needle insertion. All
doses were defined using the TG43 formalism [11].
Using simultaneously calculated dose-volume histogram
(DVH) parameters, each loading was performed under
the following restrictive indices: (i) the dose covering
90% of the prostate volume (pD90) was > 145 Gy; (ii)
the prostate volume covered by 100% of the prescribed
dose (pV100) was > 95%; (iii) the prostate volume cov-
ered by 150% of the prescribed dose (pV150) was <
60%; and (iv) the rectal volume irradiated by 100% of
the prescribed dose (rV100) was < 1.0 cc; (v) the ure-
thral volume irradiated by 150% of the prescribed dose
was 0 cc. US dosimetric figures were recorded as final
results at the end operation. On the day following
implantation as well as 30 days post-implantation, the
Table 1 Patient characteristics
All patients








Gleason Score ≦6 146
7 50
≧8 3
PSA (ng/ml) < 10 175
10-20 18
> 20 4
preHTx, history of hormone therapy before brachytherapy
PSA, prostate-specific antigen
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DVH parameters were re-calculated using pelvic CT
images obtained with a 3-mm pitch. Rectal preparation
was not performed prior to the examination. The same
physician delineated both the prostate and the rectum
on a series of CT slices. The rectum, which lies poster-
ior to the prostate, was delineated as a solid structure
defined by the outer wall, without differentiating the
inner wall or contents. Follow-up evaluations after treat-
ment were performed at 3-month intervals for a 5-year
period. Routine pre-treatment assessments of rectal
mucosal lesions by colonoscopy were not performed. At
a mean of 29 months (range, 12-48 months) after the
operation (the final follow-up date was June 30, 2010),
28 patients developed rectal bleeding, anywhere from 3
to 24 months after implantation. Of these, 17 of patients
had sporadic bleeding, whereas the remaining patients
had continual bleeding over several months. Endoscopic
assessments were performed for 16 patients and
revealed no mucosal changes (n = 11), telangiectasia (n
= 2), or radiation proctitis (n = 3). Active mucosal
bleeding was treated by photodynamic coagulation
hemostasis. Ten rectal bleeding episodes were defined as
≥ grade 2 according to the CTC-AE version 3.0 [12]
classifications based on symptoms, medication, or coa-
gulation therapy (the bled-pts). Seven patients showed
prostate-specific antigen (PSA) failure defined according
to American Society for Therapeutic Radiology and
Oncology (ASTRO) guideline [13] during the follow-up
period.
Study Design
1) Comparison of backgrounds between the bled-pts and
the others (the spared-pts)
Comparisons between them, using the t-test, were made
with regard to the rate of pretreatment hormone ther-
apy, the incidence of co-morbidities, and the mean age
at the time of the procedure. The chi-square test was
used for comparing the incidence of co-morbidities.
2) Alterations in rV100s at postoperative days 1 and 30
The alterations were evaluated by paired t-tests between
intraoperative rV100 (rV100us) and rV100 on Day 1
(rV100CT_1), or rV100CT_1 and rV100 on Day 30
(rV100CT_30). Pearson’s test was used to determine any
correlations, and linear regression analysis was per-
formed to fit the correlation.
3) Comparison of prostate volume, number of seeds
inserted, total radioactivity, and rV100s between bled-pts
and spared-pts
At each dosimetric time point, the rV100 rank was com-
pared between them by using a Mann-Whitney U test.
4) Likelihood of developing rectal bleeding in association
with rV100
For each set of rV100us, rV100CT_1, and rV100CT_30,
all patients were divided into 2 groups: those with an
rV100 (i) less than or (ii) greater than a provisional
value, and the volume was increased from 0 to 1.0 cc
stepwise in 0.1-cc increments. The ratio of the number
of bled-pts compared with spared-pts was calculated
between the 2 groups, and the likelihood of developing
rectal bleeding in the group with the larger rV100 was
expressed in terms of an odds ratio (the bled-OR). The
statistical significance was determined by a chi-square
test.
Statistical software SPSS version 11.01.j (SPSS Japan,
Tokyo, Japan) was used for data analysis. A difference
was regarded as significant if the p value was less than
0.05.
Results
1): Between the bled-pts and the spared-pts, there were
no significant differences in any of expected factors such
as age, incidence of co-morbidities, or history of hor-
mone therapy.
2): The mean values for rV100us, rV100CT_1, and
rV100CT_30 were 0.31 ± 0.43 cc, 0.22 ± 0.36 cc, and
0.59 ± 0.68 cc, respectively. There was a significant dif-
ference between these values. Although positive signifi-
cant correlations were found between rV100us and
rV100CT_1 and between rV100CT_1 and rV100CT_30,
the former correlation was as small as 0.142, while the
latter was 0.515.
3) The DVH parameters obtained by US-based and
CT-based dosimetry on postoperative days (POD) 1 and
30 for all 197 patients are summarized in Table 2. The
mean prostate dosage showed reciprocal alterations cor-
responding to differences in the mean prostate volume;
for example, a 23% decrease from US-based to CT-
based dosimetry at POD 1 corresponded to a 25%
increase in the prostate volume, and an 18% increase
from POD 1 to POD 30 on CT-based dosimetry corre-
sponded to a 19% decrease in the prostate volume.
Comparison of rV100 histograms in each planning per-
iod showed a similar distribution that was partial to the
lowest range (0-0.2 cc) (Figure 1). Between the bled-pts
Table 2 DVH parameters for each dosimetry period
Mean ± s.d.
intraoperative 1st POD 30th POD
pVol (cc) 27.9 ± 7.0 34.4 ± 9.0 27.7 ± 7.2
pD90 (Gy) 179 ± 14.1 137 ± 19.3 160 ± 18.7
pV100 (%) 97.4 ± 2.5 85.8 ± 9.9 92.7 ± 6.0
pV150 (%) 67.6 ± 10.2 44.7 ± 12.4 62.5 ± 13.5
RV100 (cc) 0.31 ± 0.43 0.23 ± 0.36 0.6 ± 0.68
RV150 (cc) 0.03 ± 0.07 0.02 ± 0.06 0.07 ± 0.16
pVol, prostate volume; pD90, dose covering 90% of prostate volume; pV100
and pV150, volume covered by 100% and 150% of the prescription dose,
respectively; rV100 and rV150, rectal volume covered by 100% and 150% of
prescription dose, respectively
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and the spared-pts there was no significant difference in
the mean values for rV100us (0.43 ± 0.31 vs 0.30 ±
0.43), rV100CT_1 (0.62 ± 0.63 vs 0.20 ± 0.33),
rV100CT_30 (0.73 ± 0.42 vs 0.58 ± 0.69) or other dosi-
metric parameters such as prostate volume (23.8 ± 7.8
cc vs 27.9 ± 7.1 cc), number of seeds (68.3 ± 15.6 vs
73.9 ± 11.9), and total activity (23.2 ± 5.2 mCi vs 25.2 ±
4.0 mCi).
4) The bled-ORs for each provisional rV100 value for
rV100us, rV100CT_1, and rV100CT_30 are shown in
Figure 2. There were considerable differences in the
magnitude and corresponding rV100 values of maxi-
mally bled-ORs. Maximally bled-ORs with significant
chi-square p-values were observed in patients with an
rV100us value above 0.1 cc (p = 0.025; OR = 7.8; 95%
CI, 1.4-145.8), an rV100CT_1 value above 0.3 cc (p =
0.014; OR = 16.2; 95% CI, 3.9-110.7), and an
rV100CT_30 value above 0.5 cc (p = 0.019; OR = 6.3;
95% CI, 1.5-42.3). For rV100CT_1, multiple consecutive
high bled-ORs were found, whereas only a single high
bled-OR was identified among the rV100s for rV100us
and rV100CT_30.
The actual rectal bleeding rate for patients with
rV100us less than 0.1 cc is 1.1% while the rate of
rV100us greater than 0.1 cc is 8.3%. Differences in
DAY 30 prostate dose parameters, such as pD90 (154
± 19.2 Gy vs 164 ± 17.1 Gy), pV100 (91.1 ± 7.2% vs
94.1 ± 4.5%), and pV150 (59.0 ± 14.9% vs 65.4 ±
11.7%) were significant between the two groups. The
rates of PSA failure in both groups were 5/88 and 2/
109, respectively, which did not achieve statistical
significance.
Discussion
During seed implant planning, it is frequently difficult to
cover the entire prostate with the prescribed dose with-
out exposing the rectum to radiation. As interactive
implant planning facilitates fine adjustments with
prompt assessment of rectal dose-volume parameters at
every seed deposition; therefore, it is worthwhile to
establish a reliable intraoperative rV100 threshold to
avoid rectal morbidity. This retrospective study showed
that, if prostate coverage is prioritized over the sparing
of rectal mass, clinicians should be aware of the very
narrow safety range regarding the intraoperative rV100,
in order to avoid grade 2 rectal bleeding under a pre-
scription dose of 145 Gy.
In this study, the safety range differs by the timing of
dosimetry. One of the cause should be the post-implant
edema that comes to maximum on Day 1 and decreased
thereafter exponentially with the half-life (time for the
edema to decrease by 1/2) varied from 4 to 25 days
(mean 9.3 days) [14]. As the prostate edema resolved,
the distance between the most posterior implanted
seeds and the anterior surface of the rectum decreased,
and the rectal dose increased exponentially at approxi-
mately the same rate the prostate volume decreased
[15]. The shift of rV100s partially explains the rectal
dose threshold elevation from DAY 1 to DAY 30, but
does not that from intraoperative to DAY 1 during
which the edema progressed.
It has been reported that rV100us is underestimated
in comparison with rV100CT_30. Ishiyama et al.
reported that the mean rV100 in 160 patients who
underwent 125I seed implant brachytherapy on
Figure 1 Histogram of the rV100s for rV100us, rV100CT_1, and rV100CT_30.
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intraoperative US-based dosimetry and CT-based dosi-
metry on Day 30 was 0.69 cc and 1.02 cc, respectively
[7]. Taussky et al. reported that the mean rV100 in 20
patients who underwent 125I seed implant brachytherapy
increased from 0.07 cc on Day 0 to 0.67 cc on Day 30
when CT-based planning was used [8]. In this study, the
rV100CT_30 threshold for rectal bleeding was as low as
0.5 cc. As a result of the underestimation of rV100us
Figure 2 Bled-ORs with 95% CI led by each provisional rV100 for rV100us, rV100CT_1, and rV100CT_30. Asterisk indicates significant
difference proven by chi-square tests.
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and in accordance with these studies, the threshold
rV100us was approximated to be zero.
There are some limitations in this study. The bled-OR
of the patients with rV100US greater than 0.1 cc dis-
played a wide CI range. This loose correlation may
come from the difficulty to predict rectal bleeding mor-
bidity by DVH analysis of low-dose rate brachytherapy
alone, especially if radiation is administered over a per-
iod of a couple of months. During this time, the rectal
shape will change because of daily defecation and
because of the rate of exposure of the anterior wall to
full-dose radiation. Merrick et al. compared the rectal
dose in CT images obtained 3 months after 125I seed
implantation between patients with a distended rectum
and patients whose rectum was evacuated using an
enema; they found that the mean dose for the rectal
wall was increased by a factor of 1.5 in the distended
state [16]. In addition, Mueller et al. undertook a
detailed study of the location of perirectal seeds under
the hypothesis that perirectal seeds could be an inde-
pendent risk factor for rectal morbidity. Using univariate
analysis, they found that the number of perirectal seeds
is another predisposing factor for higher rectal doses
and late rectal bleeding [17]. Further analysis should be
performed about these non-dosimetry-related risk
factors.
Conclusion
There is a discrepancy in the rectal dose-volume thresh-
old for post-implant rectal bleeding between the intrao-
perative and postoperative dosimetry. During 125I seed
implantation, the rV100 safety range should be set to
nearly zero if rectal morbidity is to be avoided.
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